1. Home
  2. SLDP vs ATYR Comparison

SLDP vs ATYR Comparison

Compare SLDP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Power Inc.

SLDP

Solid Power Inc.

HOLD

Current Price

$4.49

Market Cap

876.8M

Sector

Energy

ML Signal

HOLD

Logo aTyr Pharma Inc.

ATYR

aTyr Pharma Inc.

HOLD

Current Price

$0.74

Market Cap

79.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLDP
ATYR
Founded
2011
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
876.8M
79.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
SLDP
ATYR
Price
$4.49
$0.74
Analyst Decision
Strong Buy
Buy
Analyst Count
1
6
Target Price
$7.00
$8.75
AVG Volume (30 Days)
6.4M
2.0M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$19,802,000.00
$190,000.00
Revenue This Year
$27.38
N/A
Revenue Next Year
$36.18
$18,728.88
P/E Ratio
N/A
N/A
Revenue Growth
9.85
N/A
52 Week Low
$0.68
$0.64
52 Week High
$8.86
$7.29

Technical Indicators

Market Signals
Indicator
SLDP
ATYR
Relative Strength Index (RSI) 40.45 42.35
Support Level $4.30 $0.69
Resistance Level $4.77 $0.76
Average True Range (ATR) 0.32 0.04
MACD -0.01 0.01
Stochastic Oscillator 16.67 29.49

Price Performance

Historical Comparison
SLDP
ATYR

About SLDP Solid Power Inc.

Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.

About ATYR aTyr Pharma Inc.

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

Share on Social Networks: